IN-VITRO SENSITIVITY OF HUMAN-MELANOMA CELLS TO CHEMOTHERAPEUTIC-AGENTS AND INTERFERONS

被引:10
|
作者
SCHADENDORF, D
JURGOVSKY, K
WORM, M
CZARNETZKI, BM
机构
[1] University Hospital Rudolf Virchow, Free University of Berlin, Department of Dermatology, Berlin, 13353
关键词
CHEMORESISTANCE; CHEMOTHERAPY; INTERFERONS; IN-VITRO DRUG TESTING; PLASMA PEAK LEVEL;
D O I
10.1097/00008390-199408000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of our study was to evaluate systematically the anti-proliferative effects of eight chemotherapeutic drugs as well as of four recombinant interferons (IFNs) (alpha-2a, alpha-2b, beta, gamma). All drugs and IFNs were tested separately and in combination at several concentrations on four human melanoma cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyltetrazolium (MTT) test. In all cases, drug inhibitory concentrations of chemotherapeutic agents required to kill 25% of melanoma cells (IC25) in vitro were in the range of the maximal achievable plasma peak level in vivo. Sensitivity to the anti-proliferative action of bleomycin, DTIC, doxorubicin, cisplatin and carboplatin was similar for all melanoma cell lines, whereas cell lines exposed to 5-fluorouracil (5-FU), vindesine and fotemustine differed up to 26-fold in their sensitivity. Studies with IFN showed that IFN-beta and IFN-gamma proved to be more anti-proliferative than IFN-alpha in a dose-dependent fashion in all cell lines. However, the ability of IFNs to improve cytotoxicity of chemotherapeutic agents was limited. Pre-incubation of melanoma cells with IFN as well as exposure to IFN after incubation with the drugs showed mainly additive effects (231/256). These results confirm the high chemoresistance of human melanoma cells, independently of the drug chosen. Combinations of chemotherapeutic agents with IFN will provide additional therapeutic benefit, but are unlikely to change the overall high chemoresistance of human melanoma cells.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 50 条
  • [31] DIFFERENTIATION OF LEUKEMIA-CELLS BY CHEMOTHERAPEUTIC-AGENTS
    SCHWARTZ, EL
    WIERNIK, PH
    JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (09): : 779 - 794
  • [32] IN-VITRO SENSITIVITY OF B-CLL CELLS TO FLUDARABINE AND INTERFERONS
    DIRAIMONDO, F
    PALUMBO, GA
    ROMEO, MA
    CACCIOLA, E
    MILONE, G
    IMPERA, S
    GIUSTOLISI, R
    CACCIOLA, E
    LEUKEMIA & LYMPHOMA, 1995, 17 (5-6) : 449 - 453
  • [33] IN-VITRO SENSITIVITY OF B-CLL CELLS TO FLUDARABINE AND INTERFERONS
    DIRAIMONDO, F
    GUGLIELMO, P
    PALUMBO, GA
    CACCIOLA, E
    GIUSTOLISI, R
    CACCIOLA, E
    BLOOD, 1993, 82 (10) : A563 - A563
  • [34] ANTIDOPAMINE SENSITIVITY OF HUMAN-MELANOMA
    NEIFELD, JP
    SEELIG, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 219 - 219
  • [35] MEASUREMENT OF THE EFFECT OF INTERFERONS ON CELLULAR-DIFFERENTIATION IN MURINE AND HUMAN-MELANOMA CELLS
    FISHER, PB
    MIRANDA, AF
    BABISS, LE
    METHODS IN ENZYMOLOGY, 1986, 119 : 611 - 618
  • [36] A NON-CLONOGENIC ASSAY FOR THE DETERMINATION OF THE SENSITIVITY OF LEUKEMIC-CELLS TO CHEMOTHERAPEUTIC-AGENTS
    EPSTEIN, J
    PREISLER, HD
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11): : 1569 - 1574
  • [37] SENSITIVITY OF ANAEROBIC-BACTERIA TO CHEMOTHERAPEUTIC-AGENTS (ZURICH 1984)
    WUST, J
    HARDEGGER, U
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 115 (52) : 1886 - 1890
  • [38] HETEROGENEITY AND PHENOTYPIC INSTABILITY OF CHEMOTHERAPEUTIC AND IMMUNOLOGICAL SENSITIVITY IN MURINE AND HUMAN-MELANOMA CELL CLONES
    SUPINO, R
    RODOLFO, M
    MARIANI, M
    MAPELLI, E
    TUMORI, 1992, 78 (01) : 5 - 9
  • [39] INVITRO SENSITIVITY OF PSEUDOMONAS-AERUGINOSA TO ANTIBIOTIC AND CHEMOTHERAPEUTIC-AGENTS
    PAREDES, L
    VALENZUELA, E
    CAORSI, B
    CASTILLO, M
    REVISTA MEDICA DE CHILE, 1976, 104 (09) : 615 - 619
  • [40] USE OF MICROENCAPSULATED HUMAN-TUMOR CELLS FOR INVIVO EVALUATION OF CHEMOTHERAPEUTIC-AGENTS
    GORELIK, E
    ALLEY, M
    HURSEY, M
    SHOEMAKER, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 389 - 389